Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2004

View Archived Issues

Oral consumption of green tea polyphenols curbs prostate cancer progression in vivo

5-HT2A/2C agonist improves upper airway stability in rats

Parkin gene therapy shows promise for treatment of PD

Merck & Co.: pipeline review

Three recent Merck patents cover metabotropic glutamate receptor modulators

Novel tyrosine kinase inhibitors claimed by IRM

Astex describes novel MAP kinase inhibitors and their use in inflammatory conditions

New PARP inhibitors emerge from Inotek R&D

Memorial Sloan-Kettering and Columbia U. collaboration yields novel HDAC inhibitors for cancer

New analgesic agents prepared and tested at LSU

Long-term safety of bicifadine evaluated in new phase III trial

Milestone in Merck's PER.C6-related HIV program

Diamyd to be tested in type 1 diabetes

HuMax-CD20 receives fast track designation in CLL

Cell Therapeutics enters licensing agreements for bisplatinum compounds

Wyeth seeks global approval of Tygacil

Nasonex approved in U.S. for nasal polyps

Johnson & Johnson to acquire Guidant

Serono and CancerVax form global collaboration for Canvaxin

DTS-201 set to enter clinical trials in Europe

TAP submits febuxostat NDA for management of hyperuricemia in gout

Oblimersen not active in patients with multiple myeloma, but benefits patients with CLL

New data on the activity of tipifarnib in acute myeloid leukemia

Preclinical, clinical results for CC-5013 in multiple myeloma and myelodysplastic syndromes reported

Eligard six-month depot receives FDA approval

rEV-131 for postcataract surgery impresses in preclinical study

Pfizer submits Revatio for pulmonary arterial hypertension

Eisai receives positive opinion for Zonegran in Europe

FDA approval for Kepivance

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...